Previous 10 | Next 10 |
Emmaus Life Sciences press release ( OTCQX:EMMA ): Q2 GAAP EPS of -$0.18. Revenue of $4.3M misses by $1.7M . At June 30, 2022, the company had cash and cash equivalents of $1.0 million For further details see: Emmaus Life Sciences GAAP EPS of -$0.18, revenue ...
Emmaus Life Sciences Reports Q2 2022 Financial Results and Provides Business Update PR Newswire TORRANCE, Calif. , Aug. 15, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in ...
Emmaus Life Sciences Announces Engagement of Strategic Business Relations and Professional Services Advisor PR Newswire Acorn Management Partners Will Develop and Implement a Market Awareness Program Targeting Financial Professionals TORRANCE, Calif. , ...
Vancouver, Kelowna, Delta, BC - July 8, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Mining, Biotech, eSport and Plant-Based. Today's stocks have been added to our lists of fr...
NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 23 r d Life Sciences Investor Forum are now available for on-demand viewing. REGISTER NOW OR LOG...
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with Zacks Small-Cap Research, today announced the agenda for the upcoming Life Sciences Investor Forum to be held on June 23 rd . Individual inve...
Emmaus Life Sciences press release (OTCPK:EMMA): Q1 GAAP EPS of -$0.03. Revenue of $3.23M (-39.4% Y/Y) misses by $2.77M. For further details see: Emmaus Life Sciences GAAP EPS of -$0.03, revenue of $3.23M misses by $2.77M
Emmaus Life Sciences Reports Q1 2022 Financial Results and Provides Business Update PR Newswire TORRANCE, Calif. , May 13, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA) , a commercial-stage biopharmaceutical company and leader in ...
Emmaus Life Sciences to Present at Investor Conferences in May PR Newswire TORRANCE, Calif. , April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of s...
Emmaus Life Sciences (OTCPK:EMMA) notifies the launch of an innovative full-service telehealth solution accompanied by strategic partners, including Asembia LLC, US Bioservices Corporation and UpScript IP Holdings, LLC. The platform providers will handle on-line prescribing, dispensing a...
News, Short Squeeze, Breakout and More Instantly...
Emmaus Life Sciences Incorporation Company Name:
EMMA Stock Symbol:
NYSE Market:
Emmaus Life Sciences Incorporation Website:
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program PR Newswire TORRANCE, Calif. , July 12, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceuti...
Emmaus Life Sciences Reports 2023 Financial Results PR Newswire TORRANCE, Calif. , July 3, 2024 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCPK: EMMA) , a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today r...
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...